Review proposes MitoQ for age-related cardiovascular, neuronal and skeletal muscle dysfunction
This abstract-only review argues that mitochondrial oxidative stress drives aging-related dysfunction and proposes MitoQ, a mitochondria-targeted antioxidant, as a promising strategy for cardiovascular, neuronal and skeletal muscle function. [1]
Automatic summary · not editorially reviewed
The key findings
The review states that ROS accumulation is a key mediator of aging and that defective mitochondria are both a source and a target of oxidative stress. [1]
MitoQ is described as a mitochondria-targeted antioxidant studied for scavenging mitochondria-derived ROS, with proposed effects on cardiovascular, neuronal and skeletal muscle function. [1]
The authors propose MitoQ as a promising strategy against aging-associated physiological dysfunction, without reporting human outcome data in the abstract. [1]
The source at a glance
- Study type / format
- Review abstract
- Population / context
- Aging-related physiological dysfunction in cardiovascular, neuronal and skeletal muscle function, as discussed in a review
- Summary based on
- Study abstract
- Original publication
- September 28, 2026
Review links mitochondrial oxidative stress to aging
The review describes aging as a progressive decline in cellular function, with accumulating somatic mutations, weaker homeostasis and more tissue and organ dysfunction. It states that reactive oxygen species (ROS) accumulation is a key mediator of aging. Mitochondria, the main ROS producers, accumulate defects with aging, raising mitochondrial oxidative stress. The authors say these defective mitochondria are both a source and a target of oxidative stress, forming a cycle that accelerates aging and age-related diseases.
Supporting source [1]
Proposed MitoQ targets: heart, neurons, skeletal muscle
Because of this proposed central role of mitochondrial oxidative stress, the authors call targeting mitochondria a promising therapeutic approach to prevent aging-related physiological dysfunction. They focus on MitoQ, a mitochondria-targeted antioxidant, which they say has been extensively studied for scavenging mitochondria-derived ROS owing to its lipophilic cation properties. The review explores its effects on aging-associated dysfunction in cardiovascular, neuronal and skeletal muscle function. These are proposed therapeutic directions, not demonstrated human benefits.
Supporting source [1]
Abstract-only scope: no data on doses or human outcomes
The supplied text is an abstract of a review, so the full text was not reviewed. It reports no study design, sample, follow-up, dose or measured outcome, and no human lifespan or disease results. The proposal that MitoQ could counteract aging-associated physiological dysfunction is the authors' interpretation, not a causal finding. Associations described here do not establish that MitoQ prevents or treats any condition.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No design, sample, follow-up, dose or measured outcome is reported, and the therapeutic proposal is not evidence of human benefit.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Kim S, Noh SG, Ji M, Chen K, Kuchel GA, Al-Naggar IM, Kwon OS. · europepmc.org · September 28, 2026